Skip to main content
(cannabidiol) oral solution: Now FDA Approved, Pending Rescheduling
Click here to see Press Release.
Sign up here to receive EPIDIOLEX information and availability updates.
The Lancet Publishes a Landmark Study of Our Investigational Drug, Epidiolex® (cannabidiol)
Jan 24, 2018
Greenwich Biosciences Announces FDA Approval of EPIDIOLEX® (cannabidiol) Oral Solution – the First Plant-derived Cannabinoid Prescription Medicine
The New England Journal of Medicine Publishes Results from a Phase 3 Study of Our Investigational Drug, Epidiolex® (cannabidiol oral solution)
Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the 2018 American Academy of Neurology Annual Meeting
Greenwich partners with Childhood Neurology Foundation and Indiana University to improve communication between neurologists and families of children living with epilepsy